JP2009528369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528369A5 JP2009528369A5 JP2008557383A JP2008557383A JP2009528369A5 JP 2009528369 A5 JP2009528369 A5 JP 2009528369A5 JP 2008557383 A JP2008557383 A JP 2008557383A JP 2008557383 A JP2008557383 A JP 2008557383A JP 2009528369 A5 JP2009528369 A5 JP 2009528369A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- drug
- mammal
- allograft
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 89
- 241000124008 Mammalia Species 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 25
- 239000003018 immunosuppressive agent Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 23
- 229940124589 immunosuppressive drug Drugs 0.000 claims 23
- 230000024203 complement activation Effects 0.000 claims 16
- 230000001684 chronic effect Effects 0.000 claims 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 12
- 102100031506 Complement C5 Human genes 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 8
- 229930105110 Cyclosporin A Natural products 0.000 claims 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 7
- 108010036949 Cyclosporine Proteins 0.000 claims 7
- 229960001265 ciclosporin Drugs 0.000 claims 7
- -1 OKT3 Substances 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 229960002224 eculizumab Drugs 0.000 claims 4
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 2
- 108010028773 Complement C5 Proteins 0.000 claims 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 2
- 229920000742 Cotton Polymers 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- ZSNYYEIGOZADKA-UHFFFAOYSA-N Cyclosporin L Natural products CCC1NC(=O)C(C(O)C(C)CC=CC)NC(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZSNYYEIGOZADKA-UHFFFAOYSA-N 0.000 claims 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 229960004669 basiliximab Drugs 0.000 claims 2
- 229950010231 brequinar Drugs 0.000 claims 2
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 108010047295 complement receptors Proteins 0.000 claims 2
- 102000006834 complement receptors Human genes 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
- BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 claims 2
- 229950003203 pexelizumab Drugs 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 238000010911 splenectomy Methods 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77885906P | 2006-03-02 | 2006-03-02 | |
| US60/778,859 | 2006-03-02 | ||
| PCT/US2007/005290 WO2007103134A2 (en) | 2006-03-02 | 2007-03-02 | Prolongation of survival of an allograft by inhibiting complement activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013105946A Division JP2013155202A (ja) | 2006-03-02 | 2013-05-20 | 補体活性を抑制することによる同種移植片の生存の延長 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009528369A JP2009528369A (ja) | 2009-08-06 |
| JP2009528369A5 true JP2009528369A5 (https=) | 2011-02-24 |
| JP5722524B2 JP5722524B2 (ja) | 2015-05-20 |
Family
ID=38475394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557383A Expired - Fee Related JP5722524B2 (ja) | 2006-03-02 | 2007-03-02 | 補体活性を抑制することによる同種移植片の生存の延長 |
| JP2013105946A Withdrawn JP2013155202A (ja) | 2006-03-02 | 2013-05-20 | 補体活性を抑制することによる同種移植片の生存の延長 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013105946A Withdrawn JP2013155202A (ja) | 2006-03-02 | 2013-05-20 | 補体活性を抑制することによる同種移植片の生存の延長 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100135992A1 (https=) |
| EP (2) | EP1988882B1 (https=) |
| JP (2) | JP5722524B2 (https=) |
| KR (2) | KR101527225B1 (https=) |
| CN (1) | CN101437501B (https=) |
| AU (1) | AU2007224250B2 (https=) |
| BR (1) | BRPI0708424A2 (https=) |
| CA (1) | CA2644020C (https=) |
| DK (1) | DK1988882T3 (https=) |
| ES (1) | ES2530637T3 (https=) |
| HR (1) | HRP20150182T1 (https=) |
| IL (1) | IL193623A0 (https=) |
| MX (1) | MX2008011054A (https=) |
| NZ (1) | NZ570802A (https=) |
| PL (1) | PL1988882T3 (https=) |
| PT (1) | PT1988882E (https=) |
| RS (1) | RS53864B1 (https=) |
| RU (1) | RU2445975C2 (https=) |
| SG (1) | SG171578A1 (https=) |
| SI (1) | SI1988882T1 (https=) |
| WO (1) | WO2007103134A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| EP2073898A1 (en) | 2006-10-10 | 2009-07-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement inhibition for improved nerve regeneration |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20130028897A1 (en) * | 2009-04-27 | 2013-01-31 | Ali Naji | Methods for reducing the level of alloantibodies in a subject |
| CA2766565A1 (en) * | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| WO2011003098A1 (en) * | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CN101621801B (zh) * | 2009-08-11 | 2012-11-28 | 华为终端有限公司 | 无线局域网的认证方法、系统及服务器、终端 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| SG194802A1 (en) * | 2011-05-16 | 2013-12-30 | Genzyme Corp | Induction of immune tolerance by using methotrexate |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| CN103232542B (zh) * | 2013-02-01 | 2015-05-13 | 殷勇 | 一种双靶标嵌合蛋白 |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| CA2920293A1 (en) * | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| EP4162947A1 (en) * | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| JP7221691B2 (ja) * | 2015-10-30 | 2023-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法 |
| HUE065073T2 (hu) * | 2015-12-18 | 2024-04-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| EP3463459A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | Tesidolumab for use in the treatment of transplant rejection |
| US20190127453A1 (en) * | 2016-06-07 | 2019-05-02 | Novartis Ag | An anti-c5 antibody dosing regimen |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| CN111449050A (zh) * | 2019-01-20 | 2020-07-28 | 睿诺医疗科技（上海）有限公司 | 环孢菌素类似物及其用途 |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| AU2020363688A1 (en) | 2019-10-12 | 2022-04-21 | Farsight Medical Technology (Shanghai) Co., Ltd. | Treatment and prevention of nephrotoxin-induced kidney injuries |
| WO2021146471A2 (en) * | 2020-01-15 | 2021-07-22 | The Regents Of The University Of California | Transplanted cell protection via inhibition of polymorphonuclear cells |
| AU2021256222A1 (en) | 2020-04-15 | 2022-10-06 | Farsight Medical Technology (Shanghai) Co., Ltd. | Prevention and treatment of organ injuries |
| CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2588579B2 (ja) | 1988-04-21 | 1997-03-05 | 株式会社クラレ | 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法 |
| US5573940A (en) | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| US20010018051A1 (en) * | 1990-04-09 | 2001-08-30 | White David James Graham | Inhibition of allograft and concordant xenograft rejection |
| AU9149791A (en) * | 1990-12-06 | 1992-07-08 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US6355242B1 (en) * | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
| AU748443B2 (en) | 1998-02-04 | 2002-06-06 | General Hospital Corporation, The | Costimulatory blockade and mixed chimerism in transplantation |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| WO2000027421A2 (en) | 1998-11-06 | 2000-05-18 | The Schepens Eye Research Institute, Inc. | LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| AUPQ431299A0 (en) | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
| US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
| EP2896631A1 (en) | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| BR0209319A (pt) * | 2001-06-08 | 2004-07-20 | Novartis Ag | Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina |
| ES2283594T5 (es) * | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| AU2003209308A1 (en) * | 2002-01-22 | 2003-09-02 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection |
| WO2004019891A2 (en) * | 2002-08-28 | 2004-03-11 | Sangstat Medical Corporation | Methods and compostions for immune tolerance |
| US7923010B2 (en) * | 2003-09-11 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| EP2338511A3 (en) * | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| BRPI0511272A (pt) * | 2004-05-17 | 2007-12-04 | Combinatorx Inc | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios |
-
2007
- 2007-03-02 JP JP2008557383A patent/JP5722524B2/ja not_active Expired - Fee Related
- 2007-03-02 PT PT77520187T patent/PT1988882E/pt unknown
- 2007-03-02 ES ES07752018T patent/ES2530637T3/es active Active
- 2007-03-02 SG SG201102357-9A patent/SG171578A1/en unknown
- 2007-03-02 CA CA2644020A patent/CA2644020C/en not_active Expired - Fee Related
- 2007-03-02 PL PL07752018T patent/PL1988882T3/pl unknown
- 2007-03-02 RU RU2008139118/15A patent/RU2445975C2/ru not_active IP Right Cessation
- 2007-03-02 DK DK07752018.7T patent/DK1988882T3/en active
- 2007-03-02 EP EP07752018.7A patent/EP1988882B1/en not_active Revoked
- 2007-03-02 NZ NZ570802A patent/NZ570802A/en not_active IP Right Cessation
- 2007-03-02 KR KR1020087023398A patent/KR101527225B1/ko not_active Expired - Fee Related
- 2007-03-02 RS RS20150109A patent/RS53864B1/sr unknown
- 2007-03-02 KR KR1020147028450A patent/KR101650264B1/ko not_active Expired - Fee Related
- 2007-03-02 HR HRP20150182TT patent/HRP20150182T1/hr unknown
- 2007-03-02 AU AU2007224250A patent/AU2007224250B2/en active Active
- 2007-03-02 BR BRPI0708424-2A patent/BRPI0708424A2/pt not_active IP Right Cessation
- 2007-03-02 MX MX2008011054A patent/MX2008011054A/es active IP Right Grant
- 2007-03-02 CN CN200780015830XA patent/CN101437501B/zh active Active
- 2007-03-02 EP EP14198274.4A patent/EP2918269A1/en not_active Withdrawn
- 2007-03-02 WO PCT/US2007/005290 patent/WO2007103134A2/en not_active Ceased
- 2007-03-02 SI SI200731610T patent/SI1988882T1/sl unknown
- 2007-03-02 US US12/224,567 patent/US20100135992A1/en not_active Abandoned
-
2008
- 2008-08-21 IL IL193623A patent/IL193623A0/en unknown
-
2013
- 2013-05-20 JP JP2013105946A patent/JP2013155202A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528369A5 (https=) | ||
| RU2008139118A (ru) | Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента | |
| CN105073110B (zh) | 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物 | |
| JP2007537299A5 (https=) | ||
| JP5590624B2 (ja) | 補体活性を阻害することによる同種移植片の生存の延長 | |
| JP2010534243A5 (https=) | ||
| CA2801241C (en) | Methods for treating bipolar disorder | |
| Post et al. | Immunosuppression in liver transplantation | |
| JP2013501056A5 (https=) | ||
| RU2625222C2 (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| CN103561744A (zh) | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮在治疗免疫相关性和炎症性疾病中的用途 | |
| JP6129155B2 (ja) | 同種移植片拒絶反応を抑制する方法 | |
| US9156912B2 (en) | Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect | |
| JP2014505056A5 (https=) | ||
| US20080199478A1 (en) | Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections | |
| JP2006508099A5 (https=) | ||
| JP2024534926A5 (https=) | ||
| JP2016050181A (ja) | 血管炎治療剤 | |
| JP2008543822A5 (https=) | ||
| US20240197816A1 (en) | Composition and method for prolong survival of transplant and recipient | |
| JP2023500352A (ja) | 移植片対宿主病を予防又は治療するための化合物 | |
| JP2007510661A5 (https=) | ||
| Siemionow et al. | Clinical application of composite tissue allografts | |
| HK40124218A (zh) | 延长移植物和受体存活期的组合物和方法 | |
| FUJII et al. | FINAL ACCEPTED VERSION G-00496-2005. R1 |